Get startedLog in
    Picture of Pacira Biosciences logo

    PCRX — Pacira Biosciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapSuper Stock
    All News

    Pacira Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

    Picture of Pacira Biosciences logoPacira Biosciences
    08/05/2025 22:01
    Pacira Biosciences Inc PCRX.OQ reported quarterly adjusted earnings of 62 cents​​ per share for the quarter ended March 31, identical to the same quarter last year.  The mean expectation of seven analysts for the quarter was for earnings of 60 cents per share. Wall Street expected results to range from 49 cents to 76 cents per share.

Revenue rose 1.1% to $168.92 million from a year ago; analysts expected $176.03 million.

Pacira Biosciences Inc's reported EPS for the quarter was 10 cents​.

The company reported quarterly net income of $4.81 million.

Pacira Biosciences Inc shares had risen by 1.3% this quarter and gained 33.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 23.2% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "hold"

Wall Street's median 12-month price target for Pacira Biosciences Inc is $32.00

This summary was machine generated from LSEG data May 8 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)


    QUARTER ENDINGESTIMATEACTUALBEAT, MET, MISSED
    Mar. 31 20250.600.62Beat
    Dec. 31 20240.840.91Beat
    Sep. 30 20240.700.79Beat
    Jun. 30 20240.700.89Beat

    Recent news on Pacira Biosciences

    See all news